NASDAQ:GERN - Geron Stock Price, Forecast & News

Geron's stock was trading at $1.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GERN stock has increased by 3.9% and is now trading at $1.07. View which stocks have been mosted impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Geron.

Geron is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Geron.

Geron Co. (NASDAQ:GERN) posted its quarterly earnings results on Thursday, March, 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.05. The biopharmaceutical company earned $0.17 million during the quarter, compared to analysts' expectations of $0.14 million. Geron had a negative return on equity of 44.66% and a negative net margin of 14,901.74%. During the same period last year, the company posted ($0.04) earnings per share. View Geron's earnings history.

4 analysts have issued 12-month price targets for Geron's stock. Their forecasts range from $3.00 to $4.00. On average, they expect Geron's share price to reach $3.63 in the next year. This suggests a possible upside of 238.8% from the stock's current price. View analysts' price targets for Geron.

News stories about GERN stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Geron earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the next few days. View the latest news aboutGeron.

Some companies that are related to Geron include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Portola Pharmaceuticals (PTLA), TransEnterix (TRXC), Sarepta Therapeutics (SRPT), Amarin (AMRN), Anavex Life Sciences (AVXL), Puma Biotechnology (PBYI), Dynavax Technologies (DVAX), Bristol-Myers Squibb (BMY) and Advanced Micro Devices (AMD).

Geron trades on the NASDAQ under the ticker symbol "GERN."

Geron's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State Street Corp (1.82%), Geode Capital Management LLC (1.24%), Charles Schwab Investment Management Inc. (0.60%), Bank of America Corp DE (0.57%), Bank of New York Mellon Corp (0.41%) and Nuveen Asset Management LLC (0.35%). Company insiders that own Geron stock include Elizabeth G O'farrell, Melissa Kelly Behrs, Robert J Spiegel and Stephen Rosenfield. View institutional ownership trends for Geron.

GERN stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, New York State Common Retirement Fund, Credit Suisse AG, UBS Asset Management Americas Inc., and Nuveen Asset Management LLC. View insider buying and selling activity for Geron.

GERN stock was acquired by a variety of institutional investors in the last quarter, including Bank of America Corp DE, California Public Employees Retirement System, Cambridge Investment Research Advisors Inc., Alpine Global Management LLC, Goldman Sachs Group Inc., State Street Corp, UBS Group AG, and Geode Capital Management LLC. View insider buying and selling activity for Geron.

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GERN stock can currently be purchased for approximately $1.07.

Geron has a market capitalization of $214.37 million and generates $460,000.00 in revenue each year. The biopharmaceutical company earns $-68,550,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Geron employs 17 workers across the globe. View additional information about Geron.

The official website for Geron is http://www.geron.com/.

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]